ALZN
Alzamend Neuro, Inc.Company with tickers: ALZN
CIK
1677077
CUSIP
02262M605
Shares Outstanding
3,804,741
13F Activity (30d)
9 filings
8 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $2,197,654 | USD | 2026-01-31 | 10-Q | 2026-03-11 |
| Research & Development | $1,278,629 | USD | 2026-01-31 | 10-Q | 2026-03-11 |
| Operating Income | $-2,197,654 | USD | 2026-01-31 | 10-Q | 2026-03-11 |
| Net Income | $-2,198,991 | USD | 2026-01-31 | 10-Q | 2026-03-11 |
| EPS (Basic) | $-0.58 | USD/shares | 2026-01-31 | 10-Q | 2026-03-11 |
| EPS (Diluted) | $-0.58 | USD/shares | 2026-01-31 | 10-Q | 2026-03-11 |